Year All20232022202120202019 Jun 27, 2020 Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting Jun 17, 2020 Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting Jun 11, 2020 Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease Mar 23, 2020 Verve Therapeutics’ CEO Sekar Kathiresan to Speak at Wall Street Journal Health Forum Oct 03, 2019 Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer Oct 02, 2019 Verve Therapeutics to Present at the 2019 Jefferies Gene Therapy/Editing Summit Sep 16, 2019 Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board May 07, 2019 Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV
Jun 27, 2020 Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting
Jun 17, 2020 Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting
Jun 11, 2020 Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease
Oct 03, 2019 Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer
Sep 16, 2019 Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board
May 07, 2019 Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV
